Fox Chase Cancer Center News

PHILADELPHIA (January 15, 2019) — Fox Chase Cancer Center researchers have found important and unexpected relationships between cytokines, tumor-elicited inflammation and the role of intestinal microbiota.

PHILADELPHIA (January 15, 2019) — There is an opportunity to make a greater difference by identifying biomarkers and mutations that will help oncologists select the most effective treatments for individual patients.

PHILADELPHIA (January 11, 2019) — Readily available administrative databases are a cost-effective tool for investigating treatments for non-prostate genitourinary cancer and identifying research gaps and novel therapies, 

Jefferson to pursue purchase of Fox Chase Cancer Center

Two of Philadelphia’s leading academic and healthcare organizations have signed an agreement that creates an exclusive 90-day window within which to consider and negotiate the acquisition and conduct due diligence by Jefferson of the Fox Chase Cancer Center.

The move opens the door to bring together significant complementary expertise in cancer treatment and breakthrough research to improve patient outcomes across the greater Philadelphia region and beyond.

PHILADELPHIA (January 8, 2019) — Using next-generation sequencing (NGS) based RNA-sequencing, researchers at Fox Chase Cancer Center identified two new members of MiT family translocation renal cell carcinoma, NEAT1-TFE3 and KAT6A-TFE3, further emphasizing the genetic complexity of this group of renal tumors.

PHILADELPHIA (January 8, 2019) — Fox Chase Cancer Center researchers are exploring the structural mechanisms that allows pancreatic ductal adenocarcinoma (PDAC) to spread, and a new paper suggests that altering underlying substrates could harness the body’s ability to restrict the disease’s progress.

The beginning of the New Year is a perfect time to reflect on your health and to learn ways you can reduce your risk for cancer. 

With this grant, the Sykes lab will seek to uncover molecular targets that can serve as a basis for developing novel acute myeloid leukemia (AML) therapies.